NO944853L - Glukagonlignende peptid og insulinotropinderivater - Google Patents

Glukagonlignende peptid og insulinotropinderivater

Info

Publication number
NO944853L
NO944853L NO944853A NO944853A NO944853L NO 944853 L NO944853 L NO 944853L NO 944853 A NO944853 A NO 944853A NO 944853 A NO944853 A NO 944853A NO 944853 L NO944853 L NO 944853L
Authority
NO
Norway
Prior art keywords
derivatives
insulinotropin
truncated
glp
glucagon
Prior art date
Application number
NO944853A
Other languages
English (en)
Norwegian (no)
Other versions
NO944853D0 (no
Inventor
Glenn C Andrews
Gaston O Daumy
Michael L Francoeur
Eric R Larson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO944853D0 publication Critical patent/NO944853D0/no
Publication of NO944853L publication Critical patent/NO944853L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO944853A 1992-06-15 1994-12-14 Glukagonlignende peptid og insulinotropinderivater NO944853L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89907392A 1992-06-15 1992-06-15
PCT/US1993/003388 WO1993025579A1 (en) 1992-06-15 1993-04-14 Glucagon-like peptide and insulinotropin derivatives

Publications (2)

Publication Number Publication Date
NO944853D0 NO944853D0 (no) 1994-12-14
NO944853L true NO944853L (no) 1994-12-14

Family

ID=25410453

Family Applications (1)

Application Number Title Priority Date Filing Date
NO944853A NO944853L (no) 1992-06-15 1994-12-14 Glukagonlignende peptid og insulinotropinderivater

Country Status (19)

Country Link
EP (2) EP0646128A1 (pl)
JP (1) JP2575298B2 (pl)
KR (1) KR0154880B1 (pl)
CN (1) CN1057098C (pl)
AU (1) AU671117B2 (pl)
BR (1) BR9306551A (pl)
CA (1) CA2138161C (pl)
CZ (1) CZ315594A3 (pl)
FI (1) FI932722L (pl)
HR (1) HRP930993A2 (pl)
HU (2) HUT64367A (pl)
IL (1) IL105928A0 (pl)
MX (1) MX9303554A (pl)
NO (1) NO944853L (pl)
PL (1) PL176007B1 (pl)
RU (1) RU2128663C1 (pl)
SK (1) SK155694A3 (pl)
WO (1) WO1993025579A1 (pl)
YU (1) YU41493A (pl)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138486B2 (en) 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
GB9409496D0 (en) 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US5574008A (en) * 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
WO1996017941A2 (en) * 1994-12-07 1996-06-13 Bionebraska, Inc. Production of c-terminal amidated peptides from recombinant protein constructs
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5747453A (en) 1995-06-06 1998-05-05 Alza Corporation Method for increasing the electrotransport flux of polypeptides
US6333189B1 (en) 1996-06-06 2001-12-25 Alza Corporation Method of making an electrotransport device
US6006753A (en) * 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
DK1629849T4 (en) 1997-01-07 2017-12-04 Amylin Pharmaceuticals Llc Pharmaceutical compositions comprising exedins and agonists thereof
CA2283834A1 (en) * 1997-03-31 1998-10-08 James Arthur Hoffmann Glucagon-like peptide-1 analogs
US7157555B1 (en) 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
US7223725B1 (en) 1997-11-14 2007-05-29 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
EP1066314B1 (en) 1997-11-14 2007-12-26 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
FR2777283B1 (fr) * 1998-04-10 2000-11-24 Adir Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2339326A1 (en) 1998-08-10 2000-02-24 Josephine Egan Differentiation of non-insulin producing cells into insulin producing cells by glp-1 or exendin-4 and uses thereof
NZ511931A (en) * 1998-12-07 2004-01-30 Sod Conseils Rech Applic Analogues of glucagon like peptide-1
KR100458748B1 (ko) * 1998-12-07 2004-12-03 더 어드미니스트레이터즈 오브 더 튜래인 어듀케이셔널 훤드 Ｇｌｐ-1 유사체
PT1180121E (pt) 1999-05-17 2004-03-31 Conjuchem Inc Peptidos insulinotropicos de longa duracao
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
EP1803730A1 (en) 2000-04-12 2007-07-04 Human Genome Sciences, Inc. Albumin fusion proteins
DE60136958D1 (de) 2000-12-01 2009-01-22 Takeda Pharmaceutical Verfahren zur herstellung einer zubereitung mit einer bioaktiven substanz
WO2002048192A2 (en) 2000-12-13 2002-06-20 Eli Lilly And Company Amidated glucagon-like peptide-1
MXPA04003553A (es) * 2001-10-18 2004-07-22 Bristol Myers Squibb Co Mimeticos del peptido-1 similares aglucagon humano y su uso en tratamiento de diabetes y condiciones relacionadas.
EP1997829A1 (en) 2001-12-21 2008-12-03 Human Genome Sciences, Inc. Albumin fusion proteins
MXPA04008068A (es) 2002-02-20 2004-11-26 Lilly Co Eli Metodo para administrar moleculas de glp-1.
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
JP2007537149A (ja) * 2004-01-08 2007-12-20 セラテクノロジーズ インコーポレイテッド 長時間作用性のグルカゴン様ペプチド−１類似体
ES2347902T3 (es) 2004-04-23 2010-11-22 Conjuchem Biotechnologies Inc. Canadian Corporation 4528590 Fase solida para uso en un procedimiento para la purificacion de conjugados de albumina.
US8039432B2 (en) 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
US8178495B2 (en) 2008-06-27 2012-05-15 Duke University Therapeutic agents comprising a GLP-1 receptor agonist and elastin-like peptide
AU2011274474B2 (en) * 2010-07-09 2015-06-18 Dana-Farber Cancer Institute, Inc. Stabilized insulinotropic peptides and methods of use
EP2873422A4 (en) 2012-07-10 2015-12-30 Takeda Pharmaceutical PHARMACEUTICAL PREPARATION FOR INJECTION
US10660937B2 (en) 2015-05-22 2020-05-26 The Board Of Trustees Of The Leland Stanford Junio Treatment of hyperinsulinemic hypoglycemia with GLP-1 antagonist exendin(9-39)
US20190290772A1 (en) * 2016-06-02 2019-09-26 Indiana University Research And Technology Corporation Glucagon-like peptide-1-t3 conjugates
RS66595B1 (sr) 2016-11-21 2025-04-30 Amylyx Pharmaceuticals Inc Puferisane formulacije eksendina (9-39)
EP3592376A1 (en) * 2017-03-08 2020-01-15 Intarcia Therapeutics, Inc Apparatus and methods for administration of a nauseogenic compound from a drug delivery device
CA3082033A1 (en) 2017-08-24 2019-02-28 Novo Nordisk A\S Glp-1 compositions and uses thereof
US11318191B2 (en) 2020-02-18 2022-05-03 Novo Nordisk A/S GLP-1 compositions and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990011296A1 (en) * 1989-03-20 1990-10-04 The General Hospital Corporation Insulinotropic hormone
DK0512042T3 (da) * 1990-01-24 1998-05-11 Douglas I Buckley GLP-1-analoger anvendelige ved diabetesbehandling
ATE138102T1 (de) * 1991-02-19 1996-06-15 Takeda Chemical Industries Ltd Verfahren zur herstellung von cysteinfreien peptiden
DK36492D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Praeparat
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
DK39892D0 (da) * 1992-03-25 1992-03-25 Bernard Thorens Peptid

Also Published As

Publication number Publication date
HRP930993A2 (en) 1996-12-31
NO944853D0 (no) 1994-12-14
EP0646128A1 (en) 1995-04-05
CA2138161C (en) 2003-10-21
MX9303554A (es) 1994-06-30
BR9306551A (pt) 1998-09-15
AU4027593A (en) 1994-01-04
PL176007B1 (pl) 1999-03-31
EP0969016A2 (en) 2000-01-05
HU211498A9 (en) 1995-11-28
AU671117B2 (en) 1996-08-15
RU94046251A (ru) 1996-10-27
FI932722A0 (fi) 1993-06-14
JP2575298B2 (ja) 1997-01-22
HU9301739D0 (en) 1993-09-28
FI932722A7 (fi) 1993-12-16
CA2138161A1 (en) 1993-12-23
KR0154880B1 (ko) 1998-10-15
CN1057098C (zh) 2000-10-04
HUT64367A (en) 1993-12-28
CZ315594A3 (en) 1995-07-12
FI932722L (fi) 1993-12-16
CN1085913A (zh) 1994-04-27
WO1993025579A1 (en) 1993-12-23
RU2128663C1 (ru) 1999-04-10
IL105928A0 (en) 1993-10-20
JPH07504679A (ja) 1995-05-25
KR950701937A (ko) 1995-05-17
SK155694A3 (en) 1995-05-10
YU41493A (sh) 1996-10-18

Similar Documents

Publication Publication Date Title
NO944853L (no) Glukagonlignende peptid og insulinotropinderivater
NO992557D0 (no) Bruk av GLP-1-analoger og derivater administrert perifert i regulering av fedme
DK0950096T3 (da) Anti-invasive og anti-angiogene urokinase-fragmenter og deres anvendelse
ATE164852T1 (de) Glp-1-analoga verwendbar in der diabetesbehandlung
ATE480259T1 (de) Intranasale verabreichung von glucose- regulierenden peptiden
EP0378364A3 (en) Analogues of pf4 and fragments thereof, and pharmaceutical compositions containing them
NO942840L (no) Antitrombotiske polypeptider som antagonister for binding av VWF til blodplater eller til subendotel
DE69531889D1 (de) Biologisch aktive Fragmente des Glucagon ähnlichen, insulinotropen Peptides
NO974269L (no) Lipofile peptidhormonderivater
ES2124685T3 (es) Variantes del inhibidor de la tripsina pancreatica bovina, su produccion y uso.
ES2153362T3 (es) Composiciones y procedimientos de administracion sublingual o bucal de agentes terapeuticos.
NO940436L (no) Forlenget avgivelse av peptider
DE69433371D1 (de) Polypeptid, fähig zur Inhibierung der Bindung zwischen menschliches IL-6 und dessen Rezeptor
SE9901379D0 (sv) Receptor structures
RU95106651A (ru) Аналоги дзе-тур динорфина и способ лечения толерантных состояний у пациента
DE69736634D1 (de) Antagonisten des intestinotrophen glp-2 peptides
ATE165976T1 (de) Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
EP1363945B1 (en) Modified derivatives of cck-8
ATE10364T1 (de) Retro-inverso analoga von c-terminalen pentaund hexapeptiden der verbindung p.
ATE143009T1 (de) Neue heterocyclische carbonsäuren
DE69736276D1 (de) Menschliche dnase resistent gegen actininhibitoren
AU6415994A (en) Substituted caprolactams and derivatives thereof useful for treatment of hiv disease
DE69535460D1 (de) Pharmazeutische peptide formulierungen zur behandlung von staubmilben allergie
DE10033195A1 (de) Bifunktionale Fusionsproteine aus Hirudin und TAP
DE2442995A1 (de) Proteasefreie kallikreinloesungen, ein verfahren zu ihrer herstellung aus gereinigtem kallikrein und ihre verwendung als arzneimittel

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application